Table 3 Results of the conditional logistic regression analysis for each type of hypnotic and each outcome

Benzodiazepines

 Number of hypnotics per day

1.12

(1.03–1.22)

1.17

(0.89–1.56)

1.99

(0.95–4.18)

 Injury/fracture/femoral fracture

2.93

(2.68–3.19)

5.50

(4.81–6.29)

16.75

(11.39–24.62)

 Cancer

1.11

(0.98–1.25)

1.13

(0.95–1.35)

0.91

(0.62–1.33)

 Ischemic heart disease

1.05

(0.96–1.15)

0.98

(0.87–1.12)

1.12

(0.86–1.44)

 Cerebrovascular disease

0.93

(0.86–1.01)

0.91

(0.81–1.02)

0.83

(0.66–1.05)

 Dyslipidemia

0.98

(0.90–1.06)

0.95

(0.84–1.06)

0.82

(0.65–1.04)

 Diabetes mellitus

0.99

(0.91–1.09)

0.91

(0.80–1.03)

1.02

(0.79–1.31)

 Dementia

0.99

(0.90–1.09)

0.95

(0.84–1.08)

1.08

(0.84–1.40)

 Osteoporosis

1.32

(1.21–1.45)

1.27

(1.12–1.44)

1.09

(0.86–1.39)

 Anemia

1.07

(0.97–1.19)

0.98

(0.86–1.13)

0.87

(0.66–1.15)

Non-benzodiazepines

 Number of hypnotics per day

1.21

(0.97–1.51)

1.25

(0.99–1.59)

1.16

(0.49–2.71)

 Injury/fracture/femoral fracture

2.95

(2.71–3.22)

5.85

(5.09–6.73)

17.96

(12.17–26.51)

 Cancer

1.10

(0.97–1.24)

1.17

(0.98–1.39)

0.99

(0.67–1.44)

 Ischemic heart disease

1.03

(0.94–1.12)

1.03

(0.91–1.17)

1.18

(0.91–1.53)

 Cerebrovascular disease

0.95

(0.87–1.03)

0.86

(0.77–0.96)

0.81

(0.64–1.02)

 Dyslipidemia

0.95

(0.88–1.04)

0.92

(0.82–1.03)

0.92

(0.72–1.16)

 Diabetes mellitus

0.97

(0.89–1.06)

0.97

(0.85–1.09)

1.00

(0.78–1.29)

 Dementia

1.03

(0.94–1.13)

0.99

(0.87–1.12)

1.23

(0.95–1.58)

 Osteoporosis

1.35

(1.23–1.48)

1.27

(1.13–1.44)

1.23

(0.96–1.57)

 Anemia

1.12

(1.01–1.23)

0.91

(0.79–1.05)

0.82

(0.62–1.08)

Melatonin- receptor agonists

 Number of hypnotics per day

1.03

(0.99–1.08)

1.15

(1.00–1.31)

2.84

(1.19–6.77)

 Injury/fracture/femoral fracture

2.92

(2.68–3.19)

5.86

(5.10–6.74)

19.67

(13.18–29.35)

 Cancer

1.11

(0.98–1.25)

1.15

(0.97–1.37)

0.71

(0.48–1.04)

 Ischemic heart disease

1.05

(0.95–1.14)

1.05

(0.92–1.19)

1.09

(0.84–1.40)

 Cerebrovascular disease

0.94

(0.87–1.03)

0.86

(0.77–0.97)

0.83

(0.66–1.05)

 Dyslipidemia

0.94

(0.87–1.03)

0.96

(0.85–1.08)

0.90

(0.71–1.15)

 Diabetes mellitus

0.98

(0.90–1.07)

0.95

(0.84–1.08)

1.02

(0.79–1.31)

 Dementia

0.99

(0.90–1.08)

0.96

(0.84–1.09)

1.19

(0.92–1.54)

 Osteoporosis

1.32

(1.20–1.44)

1.23

(1.09–1.40)

1.23

(0.96–1.57)

 Anemia

1.11

(1.00–1.22)

0.92

(0.80–1.05)

0.84

(0.64–1.12)

Orexin- receptor antagonists

 Number of hypnotics per day

1.43

(0.97–2.11)

1.13

(0.82–1.55)

1.19

(0.32–4.51)

 Injury/fracture/femoral fracture

2.98

(2.73–3.25)

5.79

(5.06–6.63)

15.62

(10.75–22.69)

 Cancer

1.15

(1.02–1.31)

1.14

(0.96–1.35)

0.93

(0.64–1.35)

 Ischemic heart disease

1.06

(0.97–1.16)

0.98

(0.86–1.11)

0.98

(0.76–1.26)

 Cerebrovascular disease

0.93

(0.85–1.01)

0.95

(0.85–1.07)

0.98

(0.77–1.23)

 Dyslipidemia

0.97

(0.89–1.06)

0.92

(0.82–1.03)

0.83

(0.66–1.06)

 Diabetes mellitus

0.96

(0.88–1.05)

0.94

(0.83–1.07)

0.98

(0.76–1.26)

 Dementia

0.98

(0.89–1.08)

1.01

(0.88–1.15)

1.08

(0.84–1.38)

 Osteoporosis

1.30

(1.19–1.43)

1.24

(1.10–1.41)

1.14

(0.89–1.45)

 Anemia

1.11

(1.01–1.23)

0.99

(0.86–1.13)

0.96

(0.73–1.26)